Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Social anxiety disorder.

B A Raj1, D V Sheehan

  • 1Department of Psychiatry, University of South Florida College of Medicine, Tampa, Florida, USA.

The Medical Clinics of North America
|May 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of Anxiety in Clinical Trials with Depressed Patients Using the Hamilton Depression Rating Scale.

Psychopharmacology bulletin·2016
Same author

Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder.

European psychiatry : the journal of the Association of European Psychiatrists·2011
Same author

The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder.

Psychopharmacology bulletin·2007
Same author

Nicotinic acetylcholine receptors as targets for antidepressants.

Molecular psychiatry·2002
Same author

Have drug companies hyped social anxiety disorder to increase sales. No: Efforts to relieve human suffering deserve rewards.

The Western journal of medicine·2001
Same author

Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.

The Journal of clinical psychiatry·2001
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Generalized Social Anxiety Disorder (GSAD) is more prevalent and disabling than previously understood. Effective treatments are now available, offering significant relief and protection against GSAD-related disability.

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Epidemiology

Background:

  • Generalized Social Anxiety Disorder (GSAD) was increasingly recognized in the 1990s as a significant public health concern.
  • Previous understanding underestimated the prevalence, severity, and chronic nature of GSAD.
  • The need for evidence-based treatment options for GSAD became apparent.

Purpose of the Study:

  • To review and present data on the prevalence and impact of GSAD.
  • To identify and summarize effective treatment strategies for GSAD.
  • To provide patients with GSAD substantial relief and functional protection.

Main Methods:

  • Literature review of studies published in the 1990s concerning GSAD.
  • Analysis of epidemiological data on GSAD prevalence and chronicity.

Related Experiment Videos

  • Synthesis of findings from clinical trials evaluating GSAD treatments.

    • Main Results:

    • GSAD is more common, causes greater disability, and is more chronic than previously thought.
    • A range of effective treatment options for GSAD have been identified.
    • These treatments offer patients substantial symptomatic relief.
    • Therapeutic interventions provide protection against disability associated with GSAD.

    Conclusions:

    • The 1990s marked a turning point in understanding and managing GSAD.
    • Effective treatments are available, significantly improving outcomes for individuals with GSAD.
    • Further research and clinical application of these treatments are warranted.